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Abstract 
Aims 
Although acute decompensated heart failure (ADHF) is a common cause of dyspnoea, its 
diagnosis still represents a challenge. Lung ultrasound (LUS) is an emerging point of care 
diagnostic tool, but its diagnostic performance for ADHF has not been evaluated in randomized 
studies. We evaluated, in patients with acute dyspnoea, accuracy and clinical usefulness of 
combining LUS with clinical assessment compared to the use of chest radiography (CXR) and 
Nterminal proBtype natriuretic peptide (NTproBNP) in conjunction with clinical evaluation. 
Methods and results 
This was a randomized trial conducted in two emergency departments. After initial clinical 
evaluation, patients with acute dyspnoea were classified by the treating physician according to 
presumptive aetiology (ADHF or nonADHF). Patients were subsequently randomized to 
continue with either LUS or CXR/NTproBNP. A new diagnosis, integrating the results of both 
initial assessment and the newly obtained findings, was then recorded. Diagnostic accuracy 
and clinical usefulness of LUS and CXR/NTproBNP approaches were calculated. A total of 518 
patients were randomized. Addition of LUS had higher accuracy [area under the receiver 
operating characteristic curve (AUC) 0.95] than clinical evaluation alone (AUC 0.88) in 
identifying ADHF (P < 0.01). In contrast, use of CXR/NTproBNP did not significantly increase 
the accuracy of clinical evaluation alone (AUC 0.87 and 0.85, respectively; P > 0.05). The 
diagnostic accuracy of the LUSintegrated approach was higher then that of the 
CXR/NtproBNPintegrated approach (AUC 0.95 vs. 0.87, p < 0.01). Combining LUS with the 
clinical evaluation reduced diagnostic errors by 7.98 cases/100 patients, as compared to 2.42 
cases/100 patients in the CXR/NtproBNP group.  
Conclusion 
Integration of LUS with clinical assessment for the diagnosis of ADHF in the emergency 
department seems to be more accurate than the current diagnostic approach based on CXR 
and NTproBNP. 
 
Introduction 
Dyspnoea is a common symptom in acute care medicine, accounting for almost 
4 million visits per year in the U.S. emergency departments (EDs).1 However, 
the identification of the cause of acute dyspnoea is complex and often 
inaccurate. Differential diagnosis includes multiple conditions, with acute 
decompensated heart failure (ADHF), pneumonia, obstructive pulmonary 
diseases, pulmonary embolism and asthma among the most common.2-4 In 
elderly patients, the prevalence of ADHF ranges between 45% and 55%.5, 6 In 
patients with acute dyspnoea, particularly when caused by ADHF,7, 8 
erroneous or delayed diagnoses are known to increase the risk of prolonged 
hospital stay and intensive care unit admission, and are associated with higher 
costs and mortality.9 Therefore, a rapid and accurate diagnostic workup is 
critical to the establishment of specific and effective treatment, especially in 
elderly patients with multiple comorbidities.2, 3 Current guidelines for ADHF 
diagnosis in the acute care setting recommend a workup that includes 
detailed patient history, vital signs, physical examination, electrocardiogram 
(ECG), and chest radiography (CXR).6 However, this diagnostic approach is 
often unreliable,8, 10, 11 leading to ‘uncertain’ diagnosis in up to 44% of 
patients12 and it is inconsistent with the final diagnosis in approximately one 
out of four cases.4, 13-15 The addition of natriuretic peptide measurement, 
recommended in all patients with suspected ADHF,6 improves diagnostic 
accuracy,12, 16 but the misclassification rate remains unacceptably high.10, 
17-19 
Over the past two decades, lung ultrasound (LUS) has emerged as a rapid and 
reliable tool that can be used in the bedside evaluation of patients with acute 
dyspnoea. Several observational studies and a recent metaanalysis have 
suggested that LUS has higher diagnostic accuracy for ADHF than standard 
clinical workup, CXR, and natriuretic peptides.5, 20-24 To date, no 
randomized studies comparing the diagnostic performance of LUS vs. current 
standard of care for ADHF diagnosis have been published.6, 25 Here, we 
present the results of the first to our knowledge randomized trial aimed at 
evaluating, in patients presenting with acute dyspnoea to the ED, the accuracy 
of a diagnostic approach combining LUS and clinical assessment as compared 
to the traditional ADHF diagnostic workup (clinical evaluation with CXR and 
natriuretic peptide measurement).  
Methods 
This was a randomized, multicentre, parallel group trial conducted in two 
Italian academic hospitals (‘Città della Salute e della Scienza di Torino’ 
University Hospital, Turin, and ‘Careggi’ University Hospital, Florence). The 
protocol was approved by the institutional review boards of the two hospitals. 
All patients or their legally authorized representatives provided written 
informed consent and all data were deidentified immediately afterwards. 
The primary aim of the study was the comparison of the accuracy and the 
clinical usefulness of two integrated diagnostic approaches [clinical 
examination plus LUS or plus CXR and level of Nterminal proBtype 
natriuretic peptide (NTproBNP)] for the diagnosis of ADHF among patients 
suffering from acute dyspnoea in the ED. 
The secondary aim was the assessment of the time needed for defining the 
integrated evaluation in both arms. 
The study was conducted in accordance with the principles of the Declaration 
of Helsinki for clinical research involving human subjects, and registered on 
ClinicalTrials.gov (identifier number NCT02105207).  
Patients 
We considered eligible all adult patients (age ≥ 18 years) who presented to the 
ED with acute dyspnoea, defined as either sudden onset of shortness of breath 
or increase in the severity of chronic dyspnoea in the previous 48 h.5 We 
excluded patients already mechanically ventilated with positive pressure 
(either invasively or noninvasively) at the time of first evaluation, or patients 
presenting with acute dyspnoea in the context of trauma.  
The presence of an emergency physician with expertise in LUS (i.e. who 
completed LUS training in accordance with the Italian Society of Emergency 
Medicine standards26 and performed and interpreted at least 40 LUS 
examinations5) was required for patient enrolment.  
Study protocol 
Immediately after the initial clinical evaluation [including past medical history, 
history of present illness, physical examination, arterial blood gas analysis 
(ABG) and ECG], the physician responsible for the care of the patient was 
asked to indicate the presumptive aetiology of dyspnoea, categorized as a 
dichotomous variable (ADHF or nonADHF). If both aetiologies were 
concomitantly present, he/she was asked to record the one considered most 
relevant. 
Afterwards, using computerized permuted blocks of random sizes, patients 
were randomized in a 1:1 ratio to continue the diagnostic workup with 
performance of either CXR and level of NTproBNP (CXR/NTproBNP group) or 
LUS (LUS group). A new presumptive aetiologic diagnosis, combining the 
results of both initial clinical assessment and the newly obtained findings, was 
then recorded. 
Thereafter, CXR and NTproBNP measurement were also performed in all 
patients in the LUS group, but their results were made available to the treating 
physician only after the new LUSimplemented presumptive diagnosis was 
recorded. Similarly, LUS could be performed, at physician's discretion, in 
patients enrolled in the standard of care group, but only after the 
CXR/NTproBNPimplemented diagnosis was recorded. In other words, the 
treating physician had access, during patient's ED stay, to all available test 
results but, for study data collection, his/her opinion on the cause of dyspnoea 
was recorded, in the LUS group, before CXR and NTproBNP results were 
made available, and, in the CXR/NTproBNP group, before performance of LUS. 
Therefore, although the results of those subsequent tests could have 
potentially changed his/her final diagnostic judgment and patient's 
management, the diagnoses recorded immediately after LUS and 
CXR/NTproBNP, respectively, were not affected. 
Lung ultrasound was performed by the physician responsible for patient 
enrolment and care. We used a curvilinear probe (5–2 MHz) and a previously 
described eightzone scanning protocol.27 Patients were evaluated in a sitting 
or semirecumbent position.5, 27 The presence of three or more 
Blines/intercostal space represented a positive region of increased lung 
density (i.e. interstitial syndrome). Blines are defined as laserlike, vertical, 
hyperechoic artefacts that arise from the pleural line, extend to the bottom of 
the screen without fading, and move synchronously with lung sliding.27 
Bilateral presence of three or more Blines in two or more zones was 
considered diagnostic for diffuse interstitial syndrome. The presence of pleural 
effusions was also evaluated.  
All LUS evaluations were performed using intermediatesize ultrasound 
devices equipped with three probes (Esaote MyLab5, Esaote MyLab30 Gold, 
Esaote MyLab Alpha, and Philips HD7). 
NTproBNP levels were measured using a commercially available 
electrochemiluminescence immunoassay (ECLIA; Roche Diagnostics, Mannheim, 
Germany). 
After the assessment of the integrated diagnosis, the management of the 
patient was independent of the arm allocation, and the responsible physician 
based diagnostic and therapeutic decisions on the patient's clinical needs. 
After hospital discharge or death, two expert intensivists/emergency physicians 
(A.G. and E.L.), blinded to LUS results and to initial group assignment, 
independently reviewed patients' complete medical records, including 
summaries with discharge diagnoses. The adjudication of ADHF was based on 
the 2012 European Society of Cardiology guidelines for heart failure28 (i.e. 
presence of typical symptoms and signs of heart failure resulting from an 
abnormality of cardiac structure or function). In case of disagreement, a 
cardiologist (D.C.) reviewed the entire medical records and adjudicated the 
case (Figure 1).  
The time needed to convey the integrated diagnosis (clinical evaluation plus 
LUS or clinical evaluation plus CXR/NTproBNP) was also measured and 
compared in the two groups. 
Analysis of data 
Descriptive results are presented as numbers and percentages for categorical 
variables and mean (± standard deviation, SD) or median (25th–75th 
percentiles) for continuous variables. The distributions of continuous variables 
are compared by means of the Wilcoxon–Mann–Whitney test.29 
The outcome of our experimental study is a measure of accuracy of the two 
combined diagnostic approaches for ADHF diagnosis. In particular, we 
estimated sensitivity (SE), specificity (SPE), positive predictive value (PPV), 
negative predictive value (NPV), likelihood ratios, and area under the receiver 
operating characteristic curve (AUC ROC).30 ‘Positive’ and ‘negative’ results 
were considered the diagnosis of ADHF and nonADHF, respectively. We 
compared the within group difference in accuracy by using the McNemar test 
for paired data31 and the between group difference in accuracy by using the 
chisquare test.32 
In addition, the clinical usefulness of each approach was also evaluated by 
categorybased net reclassification index (NRI), reclassification tables,33 and 
net benefit (NB), using decision curve analysis.34 NRI quantifies how many 
times the diagnosis changes by virtue of a new test result. It assesses the 
diagnostic improvement provided by each combined diagnostic approach in 
relation to the initial clinical assessment by estimating the percentage of 
subjects shifting from ADHF to nonADHF or vice versa.33 Computation of the 
NB, as for other decision analytic methods, has been proposed to evaluate 
diagnostic tests in terms of their real clinical consequences. The NB quantifies 
the possible diagnostic gain by putting on the same scale right and wrong 
diagnoses, and is defined as the benefit (of a true positive compared to a false 
negative) minus the harm (of a false positive compared to a true negative) for 
a given threshold probability of ADHF (typically, its prevalence). The decision 
curve shows the NB for all possible values of the prevalence.34, 35 
Agreement between the reviewers for defining the most likely cause of acute 
dyspnoea was calculated by using the Cohen's kappa.36 
Assuming a sensitivity of the LUS approach of approximately 95%, as reported 
in a previous multicentre study,5 80% power and a 5% alpha error, we 
estimated that a sample size of 258 patients/group would be sufficient to test 
a 10% sensitivity difference.  
Statistical analyses were conducted using STATA software, version 13.1 (Stata 
Corp., College Station, TX, USA). 
Results 
Patients 
From January 2014 to March 2015, we identified 532 eligible patients. Of these, 
518 were enrolled (411 at the ‘Città della Salute e della Scienza di Torino’ 
University Hospital) and underwent randomization, 260 to the CXR/NTproBNP 
group and 258 to the LUS group (Figure 2).  
Median age was 79 years (25th–75th percentiles: 71–85 years); 243 women 
(47%) and 275 men (53%) were enrolled. Review of patients' complete 
medical records after hospital discharge or death identified 224 patients 
(43.2%) with final diagnosis of ADHF (38.5% and 48.1% in the 
CXR/NTproBNP group and in the LUS group, respectively) and 294 patients of 
nonADHF. The final diagnoses for the latter were chronic obstructive 
pulmonary disease (COPD) exacerbations (32.7%), pneumonia (32.4%), upper 
respiratory airway infections (13.6%), pleural effusion and/or atelectasis 
(5.7%), respiratory failure in metastatic cancer patients (4.7%), interstitial 
lung diseases (4.4%), asthma acute exacerbations (3.1%), pulmonary 
embolism (1.4%), and other less frequent aetiologies (i.e. myasthenia gravis, 
pneumothorax, interstitial pneumonia, pulmonary hypertension – 2%). 
Cohen's kappa for agreement between the first two reviewers was 0.84 [95% 
confidence interval (CI) 0.79–0.88]. In 42 cases (8.1%), the third reviewer 
had to evaluate the medical records in order to solve the disagreement 
between the two other reviewers. At the end of ED evaluation, 48 patients 
(9.3%) were discharged home, 310 (59.9%) were admitted to an internal 
medicine or cardiology unit, 132 (25.5%) to an intensive care unit or high 
dependency unit, and 28 (5.4%) to shortstay observation unit (with 24 
patients subsequently discharged home). Hospital mortality rate was 7.9% 
(41/518), with 24 patients who died in the CXR/NTproBNP group and 17 in 
the LUS group. 
Table 1 summarizes patients' baseline demographic and clinical data; Table 2 
reports symptoms associated with acute dyspnoea, and clinical and laboratory 
findings detected during the initial clinical assessment.  
Table 1. Demographic, baseline characteristics and home medications of 
enrolled patients, by study arm and final diagnosis  
Study arm 
All 
patients 
(n = 518) 
Final diagnosis 
 
LUS 
(n = 258) 
CXR/NTproBNP 
(n = 260)   
ADHF 
(n = 224) 
NonADHF 
(n = 294)  
Age, years, median (25th–
75th percentiles) 
79 (70–
85) 
79 (71–85) 
79 (71–
85) 
81 (73–
86) 
77 (68–84) 
Women, n (%)  112 (43.4) 131 (50.4) 
241 
(46.9) 
107 (47.8) 136 (46.3) 
Centre, Turin/Florence, n 205/53 206/54 411/107 185/39 226/68 
Discharge from the 
ED/admission, n (%)  
19/239 
(7.4/92.6) 
29/231 
(11.2/88.8) 
48/518 
(9.3/100) 
5/219 
(2.2/97.8) 
43/251 
(14.6/85.4) 
Length of stay for admitted 
patients, days, median 
(25th–75th percentiles) 
9 (5–14) 10 (5–15) 9 (5–15) 9 (5–16) 9 (5–15) 
Ejection fraction, %, 
median (25th–75th 
percentiles)a  
52 (36–
60) 
50 (35–65) 
50 (35–
58) 
44 (35–
55) 
55 (50–60) 
Pleural effusion detected 
using LUS, n (%)b  
116 (45) 43 (42.6) 
159 
(44.3) 
110 (61.8) 49 (27.1) 
Baseline characteristics, n 
(%)  
     
Tobacco usec  130 (50.4) 118 (45.4) 
248 
(47.9) 
93 (41.5) 155 (52.7) 
COPD 106 (41.1) 101 (38.9) 
207 
(40.0) 
70 (31.3) 137 (46.6) 
Asthma 13 (5.0) 14 (5.4) 27 (5.2) 5 (2.2) 22 (7.5) 
Interstitial lung disease 12 (4.7) 8 (3.1) 20 (3.9) 3 (1.3) 17 (5.8) 
Hypertensiond  184 (71.3) 185 (71.2) 
369 
(71.2) 
174 (77.7) 195 (66.3) 
History of heart 
failured  
99 (38.4) 102 (39.2) 
201 
(38.8) 
135 (60.3) 66 (22.5) 
Ischaemic 
cardiomyopathy/CAD 
89 (34.5) 82 (31.5) 
171 
(33.0) 
94 (42.0) 77 (26.2) 
Other 
cardiomyopathies 
114 (44.2) 97 (37.3) 
211 
(40.7) 
130 (58.0) 81 (27.6) 
Diabetesd  80 (31.0) 76 (29.2) 
156 
(30.1) 
78 (34.8) 78 (26.5) 
Arrhythmiae  95 (36.8) 85 (32.7) 
180 
(34.8) 
103 (46.0) 77 (26.2) 
Dyslipidaemiad  72 (27.9) 66 (25.4) 
138 
(26.6) 
76 (33.9) 62 (21.1) 
Obesityf  52 (17.8) 44 (21.2) 96 (18.5) 44 (20.3) 52 (18.9) 
Cerebrovascular 
accidentd  
64 (24.8) 56 (21.5) 
120 
(23.2) 
49 (21.9) 71 (24.2) 
CKD/chronic dialysisg  65 (25.2) 56 (21.5) 
121 
(23.4) 
74 (33.0) 47 (16.0) 
Neoplastic diseased  56 (21.7) 58 (22.3) 
114 
(22.0) 
41 (18.3) 73 (24.8) 
Thromboembolic 
disorder 
13 (5.0) 14 (5.4) 27 (5.2) 14 (6.3) 13 (4.4) 
Study arm 
All 
patients 
(n = 518) 
Final diagnosis 
 
LUS 
(n = 258) 
CXR/NTproBNP 
(n = 260)   
ADHF 
(n = 224) 
NonADHF 
(n = 294)  
Medications, n (%)       
Diuretics 151 (58.5) 145 (55.8) 
296 
(57.1) 
148 (66.1) 148 (56.8) 
Betablockers 105 (40.7) 94 (36.2) 199 
(38.4) 
126 (56.3) 73 (24.8) 
ACE inhibitors 105 (40.7) 86 (33.1) 
191 
(36.9) 
76 (34.0) 115 (39.1) 
Antiplatelet agentsa  120 (46.5) 123 (47.3) 
243 
(46.9) 
109 (48.7) 134 (45.6) 
Anticoagulantsg  57 (22.1) 52 (20.0) 
109 
(21.0) 
64 (28.6) 45 (15.3) 
Bronchodilators 90 (34.9) 89 (34.2) 
179 
(34.6) 
56 (25.0) 123 (41.8) 
Antidiabetic agents 69 (26.7) 64 (24.6) 
133 
(25.7) 
71 (31.7) 62 (21.1) 
Steroids 72 (27.9) 75 (28.9) 
147 
(28.4) 
41 (18.3) 106 (36.1) 
Antiarrhythmic agents 39 (15.1) 34 (13.1) 73 (14.1) 42 (18.8) 31 (10.5) 
Home oxygen 35 (13.6) 34 (13.1) 69 (13.3) 25 (11.2) 44 (15.0) 
• ACE, angiotensinconvertingenzyme; ADHF, acute decompensated 
heart failure; CAD, coronary artery disease; CKD, chronic kidney 
disease; COPD, chronic obstructive pulmonary disease; CXR, chest 
radiography; ED, emergency department; LUS, lung ultrasound; 
NTproBNP, Nterminal proBtype natriuretic peptide. 
• a Acetylsalicylic acid, clopidogrel, prasugrel, ticagrelor, ticlopidine, 
tirofiban, and dipyridamole.  
• b In the CXR/NTproBNP group, LUS was performed in 101 patients. In 
total, LUS was performed in 359 patients of whom 178 affected by ADHF.  
• c Current or remote use.  
• d Any type or grade of disorder/disease.  
• e Any type of cardiac rhythm disorders.  
• f Presence or absence of obesity as reported in the ED chart.  
• g CKD defined as chronic renal failure with creatinine level > 2 mg/dL 
(> 177 mol/L).  
• g Warfarin, acenocoumarol, any type of heparin, fondaparinux, apixaban, 
rivaroxaban, dabigatran.  
Table 2. Symptoms associated with dyspnoea, and clinical and laboratory 
findings reported at presentation in the emergency department  
Study arm 
All 
patients 
(n = 518)  
Final diagnosis 
 
LUS 
(n = 258)  
CXR/NTproBNP 
(n = 260)   
ADHF 
(n = 224)  
NonADHF 
(n = 294)  
Study arm 
All 
patients 
(n = 518)  
Final diagnosis 
 
LUS 
(n = 258)  
CXR/NTproBNP 
(n = 260)   
ADHF 
(n = 224)  
NonADHF 
(n = 294)  
Associated symptoms, n 
(%)  
     
Fevera  57 (22.1) 70 (26.9) 127 (24.5) 17 (7.6) 110 (37.4) 
Dry or productive 
cough 
113 (43.8) 112 (43.1) 225 (43.4) 47 (21.0) 178 (60.5) 
Chest pain 33 (12.8) 22 (8.5) 55 (10.6) 29 (13.0) 26 (8.8) 
Palpitation 16 (6.2) 17 (6.5) 33 (6.4) 21 (9.4) 12 (4.1) 
 Physical examination findings, median (25th–75th percentiles) or n (%)  
Heart rate, b.p.m. 
90 (80–
110) 
90 (76–105) 
90 (79–
110) 
90 (74–
110) 
90 (80–108) 
Systolic blood 
pressure, mmHg 
135 (120–
158) 
140 (120–150) 
135 (120–
150) 
140 (120–
160) 
135 (120–
150) 
Diastolic blood 
pressure, mmHg 
80 (70–
90) 
80 (70–90) 80 (70–90) 80 (70–90) 80 (70–90) 
PaO2/FiO2 ratiob  
257.1 
(195.2–
314.3) 
257.1 (189.3–300) 
257.1 
(190.5–
304.8) 
266.7 
(209.8–
326.2) 
242 .9 
(183.6–
295.2) 
Respiratory rate, 
/min 
28 (22–
32) 
25 (20–30) 28 (22–30) 28 (24–32) 24.5 (20–30) 
Temperature, °C 
36.1 (36–
37.3) 
36.1 (36–37.1) 
36.1 (36–
37.1) 
36 (36–
36.2) 
36.7 (36–
37.6) 
Wheezing 73 (28.3) 64 (24.6) 137 (26.5) 32 (14.3) 105 (35.7) 
Rales 156 (60.5) 173 (66.5) 329 (63.5) 165 (73.7) 164 (55.8) 
Peripheral oedema 104 (40.3) 104 (40) 208 (40.2) 133 (59.4) 75 (25.5) 
Noninvasive 
mechanical 
ventilationb in the 
ED  
34 (13.2) 30 (11.5) 64 (12.4) 43 (19.2) 21 (7.1) 
 Laboratory findings, median (25th–75th percentiles) 
White blood cells, 
10^6 cells/L 
9150 
(7100–
12820) 
9370 (7220–
12530) 
9310 
(7145–
12715) 
9120 
(6930–
11890) 
9580 (7260–
13370) 
Haemoglobin, g/dL 
12.5 
(10.8–
13.7) 
12.5 (11–14.3) 
12.5 
(10.9–
14.1) 
11.9 
(10.5–
13.6) 
13 (11.3–
14.4) 
Platelets, 10^9 
cells/L 
237.5 
(183–
304.5) 
232 (180–305) 
235.5 
(181–305) 
232.5 
(181–301) 
236.5 
(181.5–
309.5) 
Glucose, mg/dL 
132.5 
(110–175) 
129 (109–168) 
130 (109–
171) 
141 (113–
192) 
126 (106–
160) 
Creatinine, mg/dL 
1.1 (0.8–
1.5) 
1 (0.8–1.5) 
1.1 (0.8–
1.5) 
1.3 (0.9–
1.7) 
1 (0.8–1.3) 
Sodium, mmol/L 
138 (135–
140) 
138 (135–141) 
138 (135–
141) 
139 (136–
141) 
138 (135–
140) 
Potassium, mmol/L 
4.1 (3.8–
4.5) 
4.1 (3.8–4.5) 
4.1 (3.8–
4.5) 
4.2 (3.9–
4.4) 
4.1 (3.7–
4.4) 
Study arm 
All 
patients 
(n = 518)  
Final diagnosis 
 
LUS 
(n = 258)  
CXR/NTproBNP 
(n = 260)   
ADHF 
(n = 224)  
NonADHF 
(n = 294)  
AST, IU/L 
22 (17–
32) 
21 (17–29) 21 (17–31) 23 (17–33) 20 (17–28) 
ALT, IU/L 
21 (14–
32) 
20 (14–30) 20 (14–31) 
21 (14–
34.5) 
20 (15–30) 
Troponin, ng/mL 
0.034 
(0.016–
0.058) 
0.033 (0.016–
0.070) 
0.033 
(0.016–
0.063) 
0.046 
(0.023–
0.076) 
0.024 
(0.011–
0.049) 
NTproBNP, pg/mL 
1993 
(608–
5295) 
1686 (360–6005) 
1903 
(441–
5408) 
4237 
(2011.5–
8626.5) 
695 (236–
2305) 
Ddimer, mg/L 0.7 (0.4–
1.9) 
0.9 (0.5–1.7) 
0.8 (0.43–
1.84) 
0.92 
(0.59–
1.81) 
0.77 (0.33–
1.84) 
CRP, mg/L 
19.9 (7.3–
60.2) 
23.5 (7.1–63.3) 
21.7 (7.3–
62.2) 
14.1 (5.3–
28.8) 
33.3 (11.3–
97.9) 
Lactates, mmol/L 
1.4 (0.9–
2.1) 
1.4 (0.9–2) 
1.4 (0.9–
2.1) 
1.5 (1–
2.1) 
1.3 (0.9–
1.9) 
• ADHF, acute decompensated heart failure; ALT, alanine 
aminotransferase; AST, aspartate aminotransferase; CRP, Creactive 
protein; CXR, chest radiography; ED, emergency department; LUS, lung 
ultrasound; NTproBNP, Nterminal proBtype natriuretic peptide; 
PaO2/FiO2, ratio of partial pressure of arterial oxygen and fraction of 
inspired oxygen.  
• a Tympanic temperature > 38.3°C (or > 101°F).  
• b Calculated using PaO2 (mmHg) measured at the time of the first arterial 
blood gas analysis, and FiO2 provided, as reported in the case report 
form.  
• cAny type of noninvasive mechanical ventilation.  
Other commonly performed tests, either in the ED or during hospitalization 
(but always after collection of study data outcomes — i.e., presumptive 
aetiology of dyspnoea) were: echocardiography (performed in 69.9% of 
patients enrolled in the study), computed tomography (29%), coronary 
angiography (7.4%), and Doppler sonographic study of the limbs (7.8%). 
The median number of positive lung zones among all enrolled patients was 3 
(25th–75th percentiles: 1–6). In the ADHF final diagnosis group, the median 
number of positive zones was 6 (25th–75th percentiles: 4–7), in the 
nonADHF final diagnosis group it was 1 (25th–75th percentiles: 0–3). 
Fortysix per cent of patients had zero, one or two positive zones, 6% had 
three positive zones, 11% had four positive zones, and 11% had eight positive 
zones. 
Fortyfour physicians participated in the study, enrolling a median number of 
four patients/each (25th–75th percentiles: 2–14). 
Outcomes 
Figure 3 reports accuracy, ROC curves, and AUC ROC for clinical and combined 
evaluations in the two groups (clinical examination plus LUS or clinical 
examination plus CXR/NTproBNP).  
The AUC ROC of the integrated approach in the LUS arm was significantly 
higher than that in the CXR/NTproBNP arm (94.5% vs. 87.2%, respectively; 
P < 0.01).  
The accuracy of clinical evaluation alone in the identification of ADHF was not 
significantly different between the two groups (P > 0.05). There were no 
statistically significant differences in terms of SE and SPE between clinical 
evaluation and the approach combining CXR/NTproBNP with the initial clinical 
assessment (P > 0.05). In contrast, the increase in SE and SPE between clinical 
evaluation alone and the approach combining LUS with the initial clinical 
assessment was statistically significant (P < 0.01 for SE, P < 0.05 for SPE).  
We performed additional analyses in some subgroups of patients, namely 
patients with ADHF and coexistence of COPD (online supplementary Figure 
S1), patients with preserved and reduced ejection fraction (EF) (online 
supplementary Figure S2), and patients with acute dyspnoea likely caused by 
mixed aetiology (e.g. ADHF associated with an upper respiratory tract infection, 
or an exacerbated COPD, or any type of pneumonia) (online supplementary 
Figure S3).  
An additional sensitivity analysis was performed by excluding patients with 
other possible causes of sonographic vertical artefacts/Blines. The clinical 
evaluation showed a SE of 81% (95% CI 71.9–88.2%) and 84.4% (95% CI 
76.8–90.4%), a SPE of 88.7% (95% CI 82.5–93.3%) and 90.3% (95% CI 
83.7–94.9%), a PPV of 82.7% (95% CI 73.7–89.6%) and 89.6% (95% CI 
82.5–94.5%), and a NPV of 87.5% (95% CI 81.2–92.3%) and 85.5% (95% CI 
78.3–91%) in the CXR/NTproBNP and LUS arms, respectively. In the same 
subcohort, the integrated evaluation showed a SE of 85% (95% CI 76.5–
91.4%) and 93.4% (95% CI 87.5–97.1%), a SPE of 88.7% (95% CI 82.5–
93.3%) and 95.2% (95% CI 89.8–98.2%), a PPV of 83.3% (95% CI 74.7–
90%) and 95% (95% CI 89.4–98.1%), and a NPV of 89.9% (95% CI 83.8–
94.2%) and 93.7% (95% CI 87.9–97.2%) in the CXR/NTproBNP and LUS 
arms, respectively. 
The net reclassification improvement provided by LUS was 8.9% and 4.5% for 
ADHF and nonADHF, respectively, noticeably higher than that provided for 
CXR/NTproBNP (4% and 0.6%, respectively). 
Using the prevalence of ADHF measured in our study (43%) as the threshold 
probability for a NB analysis, the use of the current standard ADHF diagnostic 
workup (clinical evaluation plus CXR/NTproBNP) would reduce the 
diagnostic errors of the clinical assessment alone by 2.42 cases/100 patients. 
In contrast, the approach combining LUS with clinical evaluation would reduce 
the diagnostic errors by 7.98 cases/100 patients. Figure 4 shows the 
reclassification tables and decision curves for each group. Table S1 reports a 
sensitivity analysis for NBs using different prevalence of ADHF.  
In total, 359 patients underwent LUS during their ED stay; 159 patients 
showed pleural effusion; the effusion was unilateral in 73 (with right pleural 
effusion in 41 cases) and bilateral in 86 patients (Table 1). Both unilateral and 
bilateral sonographic presence of pleural effusion had only moderate accuracy 
for the diagnosis of ADHF, with a SE of 36.4% (95% CI 27.4–46.3%) and 
51.1% (95% CI 42.5–59.6%), and SPE of 79.5% (95% CI 72.6–85.4%) and 
89.8% (95% CI 83.7–94.2%), respectively.  
The median time needed to formulate the diagnostic hypothesis, measured 
from the time when the first diagnostic hypothesis was recorded to when the 
integrated diagnosis taking onto account the results of the following tests 
(CXR/NTproBNP or LUS, respectively) was formulated, was 104.5min 
(25th–75th percentiles: 80–131.5min) in the CXR/NTproBNP group, and 
5min (25th–75th percentiles: 4–9min) in the LUS group (P<0.01).  
A diagnostic algorithm in which LUS is integrated with the other diagnostic 
tests is presented in the online supplementary Figure S4.  
Discussion 
In this trial we found that, in adult patients presenting to the ED with acute 
dyspnoea, a diagnostic approach combining LUS with clinical evaluation 
outperforms the current standard diagnostic workup (based on clinical 
evaluation plus CXR and NTproBNP measurement) in the diagnosis of ADHF. 
In particular, in our study, adding LUS to the initial clinical assessment (i.e. 
past medical history, history of present illness, physical examination, ABG and 
ECG) significantly increased both SE and SPE, whereas inclusion of CXR and 
NTproBNP did not improve diagnostic accuracy for ADHF. With the exception 
of a singleoperator study,37 no other randomized studies had previously 
tested this research hypothesis.  
To evaluate not only the accuracy, but also the clinical usefulness of LUS 
integration for ADHF diagnosis, we estimated NRI and NB, using reclassification 
tables and decision curve analysis, respectively. Diagnostic accuracy, by 
estimating the association between a diagnostic test and the true disease 
status, only represents a performance measure, but it does not inform on the 
clinical usefulness of a diagnostic test in the ‘real world’. ‘Useful’ tests must 
have high diagnostic accuracy, but ‘accurate’ tests do not necessarily provide a 
real clinical benefit.35 The addition of LUS was able to correctly reclassify 
8.9% of patients with ADHF, and 4.5% of patients with nonADHF causes of 
dyspnoea. Moreover, in our population, with a prevalence of ADHF similar to 
the one observed in highincome countries (40–45%), this LUS approach 
reduced diagnostic errors resulting from the initial clinical assessment in 
approximately 8 cases out of 100 patients. Addition of CXR and NTproBNP 
measurement only reduced the diagnostic error in approximately 2.5 cases out 
of 100 patients evaluated.  
Bedside LUS had shown a high diagnostic accuracy in patients presenting to 
the ED with acute respiratory conditions in several observational studies.5, 20-
22, 38, 39 In particular, detection of Blines by LUS, expression of increased 
lung density and often secondary to increased water content,27, 40 has been 
shown to be useful in diagnosing ADHF in patients presenting with acute 
dyspnoea.25 However, most of the studies addressing this issue have 
significant limitations, being either single centre studies, with a relatively small 
population,20-22, 38 or performed by a single, highly skilled investigator.37, 
41 No previous studies, including our previous prospective observational 
multicentre study,5 compared directly this approach with the standard 
workup currently recommended for ADHF diagnosis.6 
In addition, the identification of pleural effusion by LUS showed only moderate 
accuracy for the diagnosis of ADHF in patients with acute dyspnoea in our 
study, as already found in previous studies.7, 13 
In our study, the clinical examination alone showed a quite good diagnostic 
accuracy (86%), still not far from that reported (85%) by other authors.15 In 
their study, McCullough and colleagues asked the participant emergency 
physicians of seven EDs to evaluate the probability of heart failure classifying 
dyspnoeic patients in three classes of risk (low, intermediate, and high). An 
intermediate probability was reported in 27.8% of patients, but the amount of 
patients clinically classified with more certainty, i.e. low or high probability, 
was 72.2%. This can be due to the wellknown phenomenon of the 
‘intermediate choice’. When given the option to choose an ‘uncertain’ and 
maybe more ‘comfortable’ diagnosis vs. more definite diagnoses, the former is 
more often selected.42 This is the reason why, in our protocol, we purposely 
decided to dichotomize the assigned diagnoses.  
In comparison with previous studies12, 43 showing an improved accuracy of 
the natriuretic peptides compared to the clinical examination in diagnosing 
heart failure, it could be surprising that in our study adding NTproBNP and 
CXR did not ameliorate the AUC ROC of the clinical evaluation. However, both 
cited studies were intrinsically different from ours, since they tested the 
accuracy of a new diagnostic test, whereas our aim was to compare two 
integrated approaches vs. clinical examination alone. In our study, the 
integrated approach with NTproBNP and CXR still improved the accuracy of 
the clinical examination, although statistical significance was not achieved. This 
can be likely related to the difference in terms of sample size (1586 patients 
were enrolled in the Maisel's study,43 and 1256 in that of Januzzi13), and to the 
use of two diagnostic tests together, NTproBNP and CXR. CXR is known, 
indeed, to have a high rate of false negatives (about one out of five patients) 
among patients with suspected ADHF in the ED,10 and it may have contributed 
to reduce the overall accuracy of the integrated standard of care arm.  
In our study, there is a relatively high percentage of patients with elevated 
level of NTproBNP in the nonADHF group, and of patients with high 
inflammatory parameters in the ADHF group. In our opinion, these results 
suggest the presence of multiple comorbidities, rather than of dyspnoea of 
‘mixed’ origin. We would like also to stress the concept that the results of 
biomarkers were interpreted by the treating physician (and later by the 
‘adjudicators’) together with the information coming from history, physical 
examination, ECG, ABG, and other diagnostic tests, allowing a more accurate 
and complete definition of the aetiology of dyspnoea in each patient. 
We performed additional analyses for assessing the diagnostic accuracy in 
some subgroups of patients. 
First, we tested our hypothesis in patients dichotomized on the basis of their 
EF (reduced or preserved; online supplementary Figure S2). In both arms and 
in both groups, the integrated approach showed a better AUC ROC than clinical 
evaluation alone, although only the LUSintegrated diagnostic approach 
reached the statistical significance, both, compared to the clinical evaluation 
alone and to the CXR/NTproBNPintegrated approach, among ADHF patients 
with preserved EF. However, since these analyses were run on small samples 
(113 patients with reduced EF and 138 with preserved EF), these results need 
to be confirmed in other cohorts before being translated in daily clinical 
practice.  
Second, we tested the research hypothesis in patients with concomitant ADHF 
and COPD, either exacerbated or not (online supplementary Figure S1). Also in 
these patients, the use of LUS was more accurate than the integration with 
CXR/NTproBNP, and the integration with both LUS and CXR/NTproBNP 
resulted in an increase of AUC ROC compared to clinical evaluation alone, but 
the low number of patients in these subgroups does not allow us to reach 
definitive conclusions.  
A similar analysis was also performed among patients with acute dyspnoea of 
mixed aetiology, defined after chart revision of all patients (online 
supplementary Figure S3). Also in this case, the combination of LUS with 
clinical evaluation outperformed that with CXR/NTproBNP and the integration 
with both LUS and CXR/NTproBNP suggested an increase in AUC ROC 
compared to the clinical evaluation alone, although not statistically significant, 
again likely due to the low number of patients in these subcategories.  
Finally, when we exclude the few patients who had other possible causes of 
Blines (e.g. interstitial lung diseases or active dialysis), the additional 
analysis confirmed the increased performance of the LUSintegrated approach 
compared to the clinical evaluation, showing no benefit from the integration 
with NTproBNP and CXR. 
In our study, we probably did not enrol patients with ADHF presenting with 
signs and symptoms of low cardiac output but without significant lung 
congestion (i.e. without acute dyspnoea), who account for 5–10% of patients 
with ADHF.6 We can suppose that an integrated pointofcare sonographic 
approach, adding also cardiac and inferior vena cava examination to LUS, 
could represent a useful diagnostic tool in these patients, but this hypothesis 
needs to be tested in an ad hoc study. This view is supported by a recent study 
by Ohman and colleagues,44 which showed that the combination of LUS with 
an advanced echocardiographic approach, including the evaluation of left atrial 
pressure (i.e. using E/e') provides excellent accuracy in the diagnosis of ADHF. 
However, the learning curve of this tool would be surely much longer than that 
for LUS and the same authors acknowledged this limitation of the study in 
terms of external validity. In our opinion, in this patient subpopulation it is 
possible that natriuretic peptides preserve a high diagnostic performance.  
In agreement with previously published studies,20, 45 our study also showed 
that LUS significantly reduced the time needed to formulate the new diagnostic 
hypothesis, as compared to the standard diagnostic workup for ADHF, 
suggesting potential organizational and logistical benefits. In enrolling patients, 
each participating physician was asked to collect the timing at the beginning of 
clinical evaluation and that at which the integrated diagnosis was formulated. 
In the CXR/NTproBNP arm, this interval is affected by the time required to 
perform these diagnostic tests outside of the ED (transfer of blood tubes, 
analytical time, imaging—CXR was performed bedside only in 48.2% of 
patients). Whereas we acknowledge that the treating physician, in the 
meantime, evaluated other patients, and not only ‘waited for the results’, we 
decided to collect the exact time when the integrated diagnosis was formulated. 
In our institutions, but it is a common scenario also in other EDs, both in Italy 
and worldwide, even in nontertiary centres, several ultrasound machines are 
almost immediately available (i.e. present in the ED and not shared with other 
services) and this contributed to make LUS faster than 
CXR/NTproBNPintegrated evaluation. The same emergency physician 
evaluating the patient also performed LUS, with no need for external resources 
(in the EDs participating to this study, this is the usual way of proceeding, 
even outside of clinical studies). Although LUS is a wellknown 
operatordependent diagnostic tool, it has already been shown to be highly 
reproducible for both image acquisition and image interpretation even when 
performed by relatively inexperienced sonographers.38, 46 Also in a previous 
paper published by our group,5 we showed a very high agreement between 
expert and naïve operators in performing LUS in dyspnoeic patients in the ED. 
Based on these data, we think that in most of the EDs, also in nontertiary 
centres, several operators can now be considered ‘expert’ in LUS.  
The generalizability of our results is supported by several factors. Firstly, the 
demographic characteristics of our study population, in terms of advanced age 
and comorbidities, are similar to those reported in other studies and well 
reflect the ‘realworld’ ED patients.47 The advanced age and the high rate of 
comorbidity of our patients could justify a median length of stay as long as 
9days in our study, similar to that of other European but longer than in North 
American studies.48, 49 
Moreover, generalizability is warranted by the large number of patients 
enrolled by several operators with different levels of expertise (still all 
considered competent in performance of LUS according to the Italian Society of 
Emergency Medicine standards26). In addition, patient management was not 
regulated by a strict protocol, but rather left to clinical judgement and 
‘realworld’ practices. Finally, to maintain a high external validity and to avoid 
overestimation of the diagnostic accuracy of the LUS approach, we did not 
exclude patients with high risk of Blines due to other clinical conditions (e.g. 
dialysis50 and interstitial lung diseases,51 9 and 22 patients, respectively).  
Some limitations should be considered in interpreting our results. The most 
important, although common in similar studies,12, 43 is the lack of a standard 
criterion to determine the final diagnosis of ADHF. To this end, we used the 
independent review of the medical records by two expert physicians, with a 
third physician reviewing discordant cases, an approach already chosen by 
other investigators.5, 20, 38, 39 
Second, we asked both investigators and reviewers, especially in patients with 
possible multiple concomitant causes of dyspnoea (e.g. pneumonia and ADHF), 
to indicate the aetiology they considered to be the most relevant in order to 
minimize the risk of ‘intermediate level’ classification.42 Although this could 
have led to some diagnostic errors, these should have occurred in both groups 
and directions, likely not affecting our findings.  
Third, LUS, alone, is definitively characterized by the inability to discriminate 
different forms of diffuse interstitial syndrome (e.g. interstitial lung disease, 
ADHF, acute respiratory distress syndrome, interstitial pneumonitis). On the 
contrary, the integration of LUS with clinical data would increase its diagnostic 
accuracy in all these conditions.24, 52, 53 In the effort to stress the 
‘realworld’ nature of our study, we decided not to exclude patients with 
reported or suspected interstitial lung disease.  
Fourth, the proportion of adjudicated ADHF diagnoses is higher in the LUS 
group than in the CXR/NTproBNP group. This can be at least partially 
explained by a potentially less ambiguous diagnostic definition provided by LUS. 
Furthermore, although the adjudicators were blinded to the LUS results, they 
may have likely impacted on treatment and further diagnostic workup, 
potentially leading to a higher agreement between emergency physicians and 
adjudicators in the LUS group. 
Fifth, we could not enrol all consecutive patients presenting to the ED with 
acute dyspnoea, since the presence of an emergency physician with knowledge 
in LUS was required. Based on the ED discharge charts available for the 
enrolment period, we estimated that, in the worst scenario, we could have lost 
20–30% of patients with acute dyspnoea, mostly because of the ED 
overcrowding in the cold seasons. At the time of the study enrolment, more 
than 80% of staff physicians working in our ED were skilled in LUS, minimizing 
the loss of patients due to the absence of an expert provider. 
Finally, we were not able to estimate interobserver agreement for LUS, as this 
would have required repeating twice LUS in acutely ill patients, potentially 
affecting patient care and impacting on the ED resources. However, although 
LUS is obviously an operatordependent diagnostic tool, it has already been 
shown to have high repeatability and reproducibility for both image acquisition 
and image interpretation, even when performed by relatively inexperienced 
sonographers.5, 38, 46 
Our study demonstrates that, in adult patients presenting to the ED with acute 
dyspnoea, a diagnostic protocol based on the integration of LUS and clinical 
assessment is more accurate than the currently recommended diagnostic 
approach based on clinical evaluation, CXR and NTproBNP measurement. 
We do not have the ambition to modify current guidelines, but our findings are 
very encouraging regarding the efficacy of the integration of LUS with clinical 
evaluation. We think that the integration of LUS with the current diagnostic 
approach (online supplementary Figure S4) has the potential to accelerate and 
improve the accuracy of ADHF diagnosis.  
Acknowledgements 
We would like to thank all the colleagues of participating emergency 
departments for their work and collaboration. 
Conflict of interest: none to declare.  
Appendix 
Study Group on Lung Ultrasound from the Molinette and Careggi 
Hospitals 
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Grazia, Grillo Sara, Lerda Alda, Lison Davide, Merico Franca, Merletti Franco, 
Moiraghi Corrado, Novelli Giulia, Pigozzi Luca, Pivetti Sonia, Quaglia Paolo, 
Sacchi Claudia, Saglio Elisa, Segre Elisabetta, Soardo Flavia, Steri Fabio, Sozzi 
Michela, Suman Francesca, Tamone Cristina, Veglio Maria Grazia. 
Careggi University Hospital 
Allinovi Marco, Betti Laura, Bigiarini Sofia, Bondi Ernesta, Casanova Barbara, 
Castelli Matteo, Chiarlone Melisenda, Dilaghi Beatrice, Fallani Grazia, Federico 
Roberto, Giannazzo Giuseppe, Gigli Chiara, Gualtieri Simona, Haxhiraj Eriola, 
Mariannini Juri, Moroni Federico, Nencioni Andrea, Ottaviani Maddalena, 
Pavellini Andrea, Pepe Giuseppe, Ponchietti Stefano, Risso Michele, Salti 
Francesca, Ticali Piero Francesco, Trause Federica, Simone Vanni, Viviani 
Gabriele. 
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